Psychopharmacology during pregnancy

Primary Care Update for Ob/Gyns

Volumn 3, Issue 3, 1996, Pages 79-86

  Miller, Laura J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ALCOHOL CONSUMPTION; CLINICAL PROTOCOL; DEPRESSION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; FETOTOXICITY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL DECISION MAKING; OBSESSION; PATIENT EDUCATION; PREGNANCY; PRENATAL CARE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; RISK ASSESSMENT; TERATOGENICITY;

EID: 0030007684     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/1068-607X(96)86785-0     Document Type: Article

References (50)

1. Cohen LS, Rosenbaum JF, Heller VL. Panic attack-associated placental abruption: a case report. J Clin Psychiatry 1989;50:266-7.
2. Benjamin J, Benjamin M. Panic disorder masquerading as pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1993;51:81-2.
3. Miller LJ. Psychiatric medication during pregnancy: understanding and minimizing risks. Psychiatr Ann 1994;24:69-75.
4. Prentice A, Brown R. Fetal tachyarrhythmia and maternal antidepressant treatment [letter]. BMJ 1989; 298:190.
5. Webster PAC. Withdrawal symptoms in neonates associated with maternal antidepressant therapy [letter]. Lancet 1973;2:318-9.
6. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993; 150:1541-2.
7. Strain SL. Fluoxetine-initiated ovulatory cycles in two clomiphene-resistant women. Am J Psychiatry 1994;151:620.
8. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269:2246-8.
9. Shader RI. Question the experts. J Clin Psychopharm 1992;12:441.
10. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993;92:721-2.
11. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994;23: 194-205.
12. 2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 1994;269:637-45.
13. Stanford MS, Patton JH. In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol Biochem Behav 1993;45:959-62.
14. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45: 444-50.
15. Cohen LS, Friedman JM, Jefferson JW, Johnson M, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271: 146-50.
16. Sharma A, Rawat AK. Teratogenic effects of lithium and ethanol in the developing fetus. Alcohol 1986;3: 101-6.
17. Ang MS, Thorp JA, Parisi VM. Maternal lithium therapy and polyhydramnios. Obstet Gynecol 1990;76: 517-8.
18. Karlsson K, Lindstedt G, Lundberg PA, Selstam U. Transplacental lithium poisoning: reversible inhibition of fetal thyroid [letter]. Lancet 1975;1:1295.
19. Woody JN, London WL, Wilbanks GD. Lithium toxicity in a newborn. Pediatrics 1971;47:94-6.
20. Troyer WA, Pereira GR, Lannon RA, Belik J, Yoder MC. Association of maternal lithium exposure and premature delivery. J Perinatal 1993; 13:123-7.
21. Omtzigt JGC, Los FJ, Hagenars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn 1992;12: 893-7.
22. Finnell RH, Buehler BA, Kerr BM, Ager PL, Levy RH. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992;42(Suppl 5):25-31.
23. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993;69:288-91.
24. Legius E, Jaeken J, Eggermont E. Sodium valproate, pregnancy, and infantile fatal liver failure [letter]. Lancet 1987;2:1518-9.
25. Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacother 1992;26:1563-5.
26. Moslet U, Hansen ES. A review of vitamin K, epilepsy and pregnancy. Acta Neurol Scand 1992;85:39-43.
27. Van der Pol MC, Hadders-Algra M, Huisjes HJ, Touwen BCL. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am J Obstet Gynecol 1991;164:121-8.
28. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner A, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994:271:767-70.
29. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992;42(Suppl 5):32-42.
30. Markestad T, Ulstein M, Strandjord RE, Aksnes L, Aarskog D. Anticonvulsant drug therapy in human pregnancy: effects on serum concentrations of vitamin D metabolites in maternal and cord blood. Am J Obstet Gynecol 1984;150: 254-8.
31. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992; 42(Suppl 5):12-6.
32. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977;15:57-64.
33. Kris EB. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 1965;7:785-9.
34. Slone D, Siskind V, Heinonen O, Monson RR, Kaufman D, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:486-8.
35. Platt JE, Friedhoff AJ, Broman SH, Bond RN, Laska E, Lin SP. Effects of prenatal exposure to neuroleptic drugs on children's growth. Neuropsychopharmacology 1988;1:205-12.
36. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol 1989;9: 170-2.
37. Auerbach JG, Hans SL, Marcus J, Maeir S. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992;14:399-406.
38. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatrics 1980; 97:308-10.
39. Scokel PW, Jones WN. Infant jaundice after phenothiazine drugs for labor: an enigma. Obstet Gynecol 1962;20:124-7.
40. Saxen I. Cleft palate and maternal diphenhydramine intake [letter]. Lancet 1974;1:407-8.
41. Parkin DE. Probable Benadryl withdrawal manifestations in a newborn infant [letter]. J Pediatrics 1974;85: 580.
42. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977.
43. Golbe LI. Parkinson's disease and pregnancy. Neurology 1987;37: 1245-9.
44. Rosa F. Amantadine pregnancy experience [letter]. Reprod Toxicol 1994;8:531.
45. Rubin PC. Beta-blockers in pregnancy. N Engl J Med 1981;305: 1323-6.
46. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk [letter]. Am J Psychiatry 1994;151:945.
47. Kuny S, Binswanger U. Neuroleptic-induced extrapyramidal symptoms and serum calcium levels: results of a pilot study. Pharmacopsychiatry 1989;21:67-70.
48. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8:461-75.
49. Stahl MMS, Saldeen P. Reversal of fetal benzodiazepine intoxication using flumazenil. Br J Obstet Gynaecol 1993;100:185-8.
50. Edwards JG, Inman WHW, Wilton L, Pearce GL. Prescription-event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 1994;164:387-95.